Antibiotic injection in pharma franchise in Rajasthan

Antibiotic injection in PCD pharma franchise in Hyderabad

Antibiotic injection in top pharma company in Bengaluru

Antibiotic injection in pcd pharma supplier in Dispur

Antibiotic injection in phama franchise company in india
Antibiotic injection of Iron syrup in phama distributor in Bharatpur

Home/Products /ceftriaxone-500mg-tazobactum-62-point-5-mg-injection

About the Product

Description


Fritcet TZ 562.5 contains L-Ornithine L-Aspartate (5gm), an essential liver-supporting compound that aids in detoxification, liver regeneration, and ammonia elimination. This formulation is widely used for the management of liver disorders such as hepatic encephalopathy, cirrhosis, fatty liver disease, and hyperammonemia. It enhances protein metabolism and supports liver cell function, promoting overall liver health.

L-Ornithine L-Aspartate works by converting excess ammonia into urea, which is then excreted from the body, reducing the toxic load on the liver. This action is particularly beneficial for individuals suffering from chronic liver diseases, alcohol-induced liver damage, and metabolic disorders that affect liver function. Additionally, it plays a role in reducing fatigue, muscle weakness, and mental confusion associated with liver dysfunction.

By supporting the urea cycle, Fritcet TZ 562.5 helps alleviate symptoms of hepatic encephalopathy, such as cognitive impairment and lethargy, by clearing excess ammonia from the bloodstream. It also assists in improving digestion, energy levels, and overall metabolic efficiency in patients with liver disorders.

This formulation is generally administered by dissolving the prescribed dose in water, ensuring fast absorption and effectiveness. It is well-tolerated and can be used alongside other medications prescribed for liver conditions.

Common side effects may include nausea, bloating, diarrhea, or stomach discomfort. Rare side effects should be reported to a healthcare provider immediately.

Fritcet TZ 562.5 is indicated for the treatment of hepatic encephalopathy, cirrhosis, fatty liver disease, and conditions leading to hyperammonemia.

Use under medical supervision. Patients with kidney impairment should consult their doctor before use. Do not exceed the recommended dosage.

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

1. What are the business opportunities for Ceftriaxone 500 mg + Tazobactam 62.5 mg Injection in the PCD pharma franchise market?

Ceftriaxone + Tazobactam Injection is a high-demand product in the anti-infective, hospital, and critical care segment, making it a valuable addition to a PCD pharma franchise portfolio. With the continued need for injectable antibacterial therapies in hospitals and healthcare institutions, this combination enjoys strong prescription demand from physicians, surgeons, and healthcare professionals across India.

2. Why should medical distributors include Ceftriaxone + Tazobactam Injection in their product range?

Medical distributors and franchise partners can benefit from the steady demand for hospital-based anti-infective products. Commonly prescribed for the management of susceptible bacterial infections under medical supervision Combines a widely used cephalosporin antibiotic with a beta-lactamase inhibitor Frequently utilized in hospitals, nursing homes, and healthcare facilities Strong demand from physicians, surgeons, and critical care specialists Supports expansion into the high-volume injectable anti-infective segment Widely used across multiple healthcare settings This strengthens a comprehensive anti-infective and hospital care product portfolio.

3. Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Ceftriaxone 500 mg + Tazobactam 62.5 mg Injection with exclusive monopoly rights, promotional support, attractive packaging, and competitive pricing for distributors, stockists, and wholesalers throughout India.

4. What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies can benefit from: Strong demand in the hospital and anti-infective segment Consistent institutional and prescription-based sales opportunities High utilization in healthcare facilities and nursing homes Reliable product availability and supply chain support Attractive margins and business growth potential Strong acceptance among healthcare professionals These advantages contribute to sustainable sales and long-term market expansion.

5. How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and pharma entrepreneurs can partner with Cafoli LifeCare Pvt Ltd to access profitable PCD pharma franchise opportunities for Ceftriaxone 500 mg + Tazobactam 62.5 mg Injection. With exclusive monopoly rights, comprehensive promotional support, quality-assured formulations, attractive profit margins, and dependable logistics services, Cafoli LifeCare Pvt Ltd helps franchise partners establish and expand a successful pharmaceutical business across India.